Incidence of severe SAD (SIGH‐SAD‐SR (≥ 40)) ( · All participants were known SAD patients who had been successfully treated with conventional light therapy in previous winters
It is very uncertain whether light therapy changes incidence of severe SAD (SIGH‐SAD‐SR (≥ 40)) ( compared with no light therapy (very low certainty).
1 finding from 1 review
Overall discontinuation ( · All participants were known SAD patients who had been successfully treated with conventional light therapy in previous winters
It is very uncertain whether light therapy changes overall discontinuation ( compared with no light therapy (very low certainty).
1 finding from 1 review
Incidence of SAD (IDS‐SR > 20) · adults with a history of SAD but without depressive symptoms when treatment started
It is very uncertain whether mindfulness‐based cognitive therapy (MBCT) changes incidence of SAD (IDS‐SR > 20) compared with treatment (very low certainty).
1 finding from 1 review
Severity of SAD ( · adults with a history of SAD but without depressive symptoms when treatment started
1 finding from 1 review
Overall discontinuation ( · adults with a history of SAD but without depressive symptoms when treatment started
It is very uncertain whether mindfulness‐based cognitive therapy (MBCT) changes overall discontinuation rate compared with treatment (very low certainty).
1 finding from 1 review
Incidence of SAD (modified ITT) · adults with a history of SAD
It is very uncertain whether agomelatine changes incidence of SAD (modified ITT) compared with placebo (very low certainty).
1 finding from 1 review
Adverse events as N of participants with at least one adverse event subjective and objective · adults with a history of SAD
It is very uncertain whether agomelatine changes number of persons with at least one adverse event within a year compared with placebo (very low certainty).
1 finding from 1 review
Severity of depression (SIGH‐SAD score) at the end of the study · adults with a history of SAD
1 finding from 1 review
Quality of life · adults with a history of SAD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of interpersonal and social functioning · adults with a history of SAD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants experiencing at least one severe adverse event · adults with a history of SAD
It is very uncertain whether agomelatine changes number of persons with at least one severe adverse event within a year compared with placebo (very low certainty).
1 finding from 1 review
Change in depressive symptoms · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Quality of life (emotional) · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Change in dyspnoea score · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Change in exercise tolerance · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Change in hospital length of stay or readmission rates · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Cost‐effectiveness · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Change in depressive symptoms · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Adverse events · patients with chronic obstructive pulmonary disease
1 finding from 1 review
QoL · patients with chronic obstructive pulmonary disease
1 finding from 1 review